Diagnostic tests and prognostic indicators

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Siontis B et al. Blood Cancer J. 2015 Oct 23;5:e364. doi: 10.1038/bcj.2015.87. 18F-FDG PET/CT FOCAL, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Zamagni E et al. Leukemia. 2015 Oct 22. doi: 10.1038/leu.2015.291. [Epub ahead of print]. MMSA-1 expression pattern in multiple myeloma and…

Related conditions

TCL1 expression patterns in Waldenström macroglobulinemia. Lemal R et al. Mod Pathol. 2015 Oct 23. doi: 10.1038/modpathol.2015.122. [Epub ahead of print]. Cast nephropathy: an extremely rare renal presentation of Waldenström’s macroglobulinaemia. Santos T et al. BMJ Case Rep. 2015 Oct 7;2015. pii: bcr2015211210. doi: 10.1136/bcr-2015-211210. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström’s macroglobulinemia. Alfaraj WA et…

Emerging treatments

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. Mu S et al. Eur J Clin Pharmacol. 2015 Oct 22. [Epub ahead of print]. Panobinostat for the treatment of multiple myeloma: the evidence to date. Bailey H et al. J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015. Panobinostat for the treatment of relapsed…

Biology and genetics

Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. Ludwig C et al. Blood Cancer J. 2015 Oct 16;5:e359. doi: 10.1038/bcj.2015.85. Impact of cytogenetic classification on outcomes following early high dose therapy in multiple myeloma. Kaufman GP et al. Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.287. [Epub ahead of print]. Insight into human…

General

Clarification on the definition of complete response in multiple Myeloma. Durie BG et al. Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.290. [Epub ahead of print]. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.…

Supportive care

Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. Trifilio S et al. Clin Transplant. 2015 Oct 22. doi: 10.1111/ctr.12637. [Epub ahead of print]. Surgery for vertebral involvement in Multiple Myeloma. Donnarumma P et al. J Neurosurg Sci. 2015 Oct 16. [Epub ahead of print]. Effectiveness of Haemodiafiltration…

Complications of myeloma and its treatments

Endobronchial plasmacytoma in patient with multiple myeloma. Sunnetcioglu A et al. Clin Respir J. 2015 Oct 27. doi: 10.1111/crj.12408. [Epub ahead of print]. Rapid Progression of Vascular and Soft Tissue Calcification while Being Managed for Severe and Persistent Hypocalcemia Induced by Denosumab Treatment in a Patient with Multiple Myeloma and Chronic Kidney Disease. Ueki K et al. Intern Med. 2015;54(20):2637-42. doi: 10.2169/internalmedicine.54.4946. Epub 2015…

Current treatments

Sequential versus alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Mateos MV et al. Blood. 2015 Oct 23. pii: blood-2015-08-666537. [Epub ahead of print]. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Cavo M et al. Leukemia. 2015 Oct 7. doi: 10.1038/leu.2015.274. [Epub ahead of print].…

Diagnostic tests and prognostic indicators

MicroRNAs in urine are not biomarkers of multiple myeloma. Sedlaříková L et al. J Negat Results Biomed. 2015 Sep 23;14(1):16. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. Besse L et al. PLoS One. 2015 Sep 21;10(9):e0137294. doi: 10.1371/journal.pone.0137294. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly…